LYSSA
MCID: RBS001
MIFTS: 58

Rabies (LYSSA)

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Rabies

MalaCards integrated aliases for Rabies:

Name: Rabies 12 74 52 58 54 42 3 43 15 71 32
Lyssa 12 52

Characteristics:

Orphanet epidemiological data:

58
rabies
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),<1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11260
ICD9CM 34 071
MeSH 43 D011818
NCIt 49 C28182
SNOMED-CT 67 14168008
ICD10 32 A82 A82.9
MESH via Orphanet 44 D011818
ICD10 via Orphanet 33 A82.0 A82.1 A82.9
UMLS via Orphanet 72 C0034494
Orphanet 58 ORPHA770
UMLS 71 C0034494

Summaries for Rabies

MedlinePlus : 42 Rabies is a deadly animal disease caused by a virus. It can happen in wild animals, including raccoons, skunks, bats and foxes, or in dogs, cats or farm animals. People get it from the bite of an infected animal. In people, symptoms of rabies include fever, headache and fatigue, then confusion, hallucinations and paralysis. Once the symptoms begin, the disease is usually fatal. A series of shots can prevent rabies in people exposed to the virus. You need to get them right away. If an animal bites you, wash the wound well; then get medical care. To help prevent rabies Vaccinate your pet. Rabies vaccines are available for dogs, cats and farm animals Don't let pets roam Don't approach stray animals. Animals with rabies might be aggressive and vicious, or tired and weak Centers for Disease Control and Prevention

MalaCards based summary : Rabies, also known as lyssa, is related to noma and cork-handlers' disease, and has symptoms including fever and pruritus. An important gene associated with Rabies is PML (PML Nuclear Body Scaffold), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Proguanil and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are hallucinations and fever

Disease Ontology : 12 A viral infectious disease that results in inflammation located in brain or located in spinal cord, has material basis in Rabies virus, which is transmitted by bite of an infected animal, or transmitted by contact of mucous membranes with saliva of an infected animal. The infection has symptom fever, has symptom headache, has symptom prickling or itching sensation at the site of bite, has symptom anxiety, has symptom confusion, has symptom agitation, has symptom delirium, has symptom difficulty swallowing, has symptom hydrophobia, and has symptom paralysis.

CDC : 3 Rabies is a fatal but preventable viral disease. It can spread to people and pets if they are bitten or scratched by a rabid animal. In the United States, rabies is mostly found in wild animals like bats, raccoons, skunks, and foxes. However, in many other countries dogs still carry rabies, and most rabies deaths in people around the world are caused by dog bites. The rabies virus infects the central nervous system. If a person does not receive theappropriate medical care after a potential rabies exposure, the virus can cause disease in the brain, ultimately resulting in death. Rabies can be prevented by vaccinating pets, staying away from wildlife, and seeking medical care after potential exposures before symptoms start.

Wikipedia : 74 Rabies is a viral disease that causes inflammation of the brain in humans and other mammals. Early... more...

Related Diseases for Rabies

Diseases related to Rabies via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 126)
# Related Disease Score Top Affiliating Genes
1 noma 10.7 NGFR ALB
2 cork-handlers' disease 10.6 CD40LG ALB
3 fournier gangrene 10.6 CD40LG ALB
4 monoclonal paraproteinemia 10.6 NCAM1 CD40LG
5 heterophyiasis 10.5 CD40LG ALB
6 non-secretory myeloma 10.5 NCAM1 CD40LG ALB
7 sting-associated vasculopathy with onset in infancy 10.5 STAT1 IRF3 DDX58
8 kunjin encephalitis 10.5 STAT2 CD40LG
9 cryoglobulinemia, familial mixed 10.5 IFNA1 CD40LG
10 plasma cell neoplasm 10.5 NCAM1 CD40LG ALB
11 blood protein disease 10.5 NCAM1 CD40LG ALB
12 coccidiosis 10.5 TLR3 CD40LG ALB
13 splenic abscess 10.5 CD40LG ALB
14 chilblain lupus 1 10.5 IRF3 IFNA1 DDX58
15 meningovascular neurosyphilis 10.5 CD40LG ALB
16 bell's palsy 10.5 MX1 IFNA1 CD40LG
17 salmonellosis 10.5 TLR3 STAT1 ALB
18 pure red-cell aplasia 10.5 IFNA1 CD40LG ALB
19 plague 10.5 TLR3 DDX58 ALB
20 acrodermatitis 10.5 CXCL10 CD40LG ALB
21 nose disease 10.4 TLR3 CD40LG ALB
22 acalculous cholecystitis 10.4 CD40LG ALB
23 swine influenza 10.4 MX1 IFNA1 DDX58
24 commensal bacterial infectious disease 10.4 TLR3 CD40LG ALB
25 multifocal motor neuropathy 10.4 CXCL10 CD40LG
26 west nile virus 10.4 IRF3 IFNA1 DDX58
27 paracoccidioidomycosis 10.4 CXCL10 CD40LG ALB
28 exanthem 10.4 IFNA1 CD40LG ALB
29 skin squamous cell carcinoma 10.4 STAT2 STAT1 IFNA1
30 opportunistic mycosis 10.4 TLR3 STAT1 CD40LG ALB
31 gastrointestinal tuberculosis 10.4 CD40LG ALB
32 fungal infectious disease 10.4 TLR3 STAT1 CD40LG ALB
33 japanese encephalitis 10.4 TLR3 IFNA1 CXCL10
34 hypersensitivity reaction type iv disease 10.4 IFNA1 CD40LG ALB
35 bacterial infectious disease 10.4 TLR3 MX1 IRF3 CD40LG
36 selective igg deficiency disease 10.4 NCAM1 CD40LG
37 biliary atresia 10.4 TLR3 MX1 ALB
38 granulomatous hepatitis 10.4 CD40LG ALB
39 marburg hemorrhagic fever 10.4 IFNA1 CD40LG
40 bacterial pneumonia 10.4 TLR3 CD40LG ALB
41 chronic mucocutaneous candidiasis 10.4 TLR3 STAT2 STAT1 IFNA1
42 cryoglobulinemia 10.4 IFNA1 CXCL10 CD40LG
43 hepatitis e 10.4 TLR3 DDX58 CD40LG ALB
44 conjunctival disease 10.4 TLR3 IFNA1 CD40LG ALB
45 neuromyelitis optica 10.4 IFNA1 CXCL10 CD40LG
46 rectal disease 10.4 TLR3 IFNA1 CD40LG ALB
47 lassa fever 10.4 IRF3 IFNA1 DDX58 CD40LG
48 human immunodeficiency virus infectious disease 10.4 STAT1 NCAM1 MX1 IFNA1
49 leukocyte disease 10.4 NCAM1 IFNA1 CD40LG ALB
50 meningoencephalitis 10.4 TLR3 CXCL10 CD40LG ALB

Graphical network of the top 20 diseases related to Rabies:



Diseases related to Rabies

Symptoms & Phenotypes for Rabies

Human phenotypes related to Rabies:

58 31 (show all 20)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hallucinations 58 31 hallmark (90%) Very frequent (99-80%) HP:0000738
2 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
3 nausea and vomiting 58 31 hallmark (90%) Very frequent (99-80%) HP:0002017
4 attention deficit hyperactivity disorder 58 31 hallmark (90%) Very frequent (99-80%) HP:0007018
5 anxiety 58 31 hallmark (90%) Very frequent (99-80%) HP:0000739
6 depressivity 58 31 hallmark (90%) Very frequent (99-80%) HP:0000716
7 anorexia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002039
8 paresthesia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003401
9 insomnia 58 31 hallmark (90%) Very frequent (99-80%) HP:0100785
10 migraine 58 31 hallmark (90%) Very frequent (99-80%) HP:0002076
11 recurrent pharyngitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100776
12 diarrhea 58 31 hallmark (90%) Very frequent (99-80%) HP:0002014
13 vocal cord paresis 58 31 hallmark (90%) Very frequent (99-80%) HP:0001604
14 excessive salivation 58 31 hallmark (90%) Very frequent (99-80%) HP:0003781
15 cerebral palsy 58 31 frequent (33%) Frequent (79-30%) HP:0100021
16 reduced consciousness/confusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0004372
17 sudden cardiac death 58 31 occasional (7.5%) Occasional (29-5%) HP:0001645
18 seizure 31 occasional (7.5%) HP:0001250
19 behavioral abnormality 58 Very frequent (99-80%)
20 seizures 58 Occasional (29-5%)

UMLS symptoms related to Rabies:


fever, pruritus

GenomeRNAi Phenotypes related to Rabies according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.96 NCAM1
2 Decreased viability GR00240-S-1 9.96 CD40LG
3 Decreased viability GR00249-S 9.96 ALB HLA-G IRF7 MX1 PTPN4 TLR3
4 Decreased viability GR00342-S-1 9.96 TLR3
5 Decreased viability GR00342-S-2 9.96 TLR3
6 Decreased viability GR00381-A-1 9.96 DYNLL1
7 Decreased viability GR00386-A-1 9.96 ALB DHX58 DYNLL1 HLA-G OCA2 STAT2
8 Decreased viability GR00402-S-2 9.96 DHX58 NPY TLR3
9 Increased the percentage of infected cells GR00402-S-1 8.32 TLR3

MGI Mouse Phenotypes related to Rabies:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.1 ALB CD40LG CXCL10 DDX58 DHX58 DYNLL1
2 hematopoietic system MP:0005397 10.1 CD40LG CXCL10 DDX58 DHX58 DYNLL1 HLA-G
3 homeostasis/metabolism MP:0005376 10.03 ALB CD40LG CXCL10 DDX58 DHX58 DYNLL1
4 immune system MP:0005387 9.86 ALB CD40LG CXCL10 DDX58 DHX58 DYNLL1
5 mortality/aging MP:0010768 9.47 ALB CD40LG CXCL10 DDX58 DHX58 DYNLL1

Drugs & Therapeutics for Rabies

Drugs for Rabies (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Proguanil Approved Phase 4 500-92-5 4923
2
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
3
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
4
Atovaquone Approved Phase 4 95233-18-4 74989
5
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
6
Vancomycin Approved Phase 4 1404-90-6 14969 441141
7
Metronidazole Approved Phase 4 443-48-1 4173
8
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
9 Antibodies, Blocking Phase 4
10 Amebicides Phase 4
11 Anthelmintics Phase 4
12 Chloroquine diphosphate Phase 4 50-63-5
13 Analgesics, Non-Narcotic Phase 4
14 Analgesics Phase 4
15 Anti-Inflammatory Agents Phase 4
16 Atovaquone, proguanil drug combination Phase 4
17 Antimalarials Phase 4
18 Antimetabolites Phase 4
19 Antirheumatic Agents Phase 4
20 Anti-Inflammatory Agents, Non-Steroidal Phase 4
21 Anti-Infective Agents Phase 4
22 Antiprotozoal Agents Phase 4
23 Antiparasitic Agents Phase 4
24 Anti-Bacterial Agents Phase 4
25 Antibiotics, Antitubercular Phase 4
26 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
27
Lactitol Approved, Investigational Phase 3 585-88-6, 585-86-4 493591
28
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
29
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
30
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
31 Immunoglobulins, Intravenous Phase 3
32 Rho(D) Immune Globulin Phase 3
33 gamma-Globulins Phase 3
34 Pharmaceutical Solutions Phase 3
35
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
36
Abacavir Approved, Investigational Phase 2 136470-78-5 441300 65140
37
Efavirenz Approved, Investigational Phase 2 154598-52-4 64139
38
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
39
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
40
Zidovudine Approved Phase 2 30516-87-1 35370
41
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
42 Cytochrome P-450 Enzyme Inhibitors Phase 2
43 Anti-HIV Agents Phase 2
44 Antiviral Agents Phase 2
45 Anti-Retroviral Agents Phase 2
46 Cyclosporins Phase 2
47 Antifungal Agents Phase 2
48 Reverse Transcriptase Inhibitors Phase 2
49 Calcineurin Inhibitors Phase 2
50 Immunosuppressive Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 119)
# Name Status NCT ID Phase Drugs
1 Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose Unknown status NCT01173302 Phase 4
2 Diagnostic Immunization With Rabies Vaccine in Patients With Primary Immunodeficiency Disorders Unknown status NCT02490956 Phase 4
3 Immunogenicity and Safety of Purified Vero Cell Rabies Vaccine (PVRV, Verorab™) Administered for Rabies Post-exposure Treatment. Comparison of Essen-IM, Zagreb-IM, and Thai Red Cross (TRC)-ID Regimens in the Indian Population. Completed NCT00260351 Phase 4
4 Phase 4 Study of Speeda® Rabies Vaccinia That Use for Protection the Crowd Bitten by Animals to Three-level Completed NCT01827917 Phase 4
5 Effect of Antimalarial Drugs on the Immune Response to Rabies Vaccine for Post-exposure Prophylaxis. A Randomized, Open Label, Trial in Healthy US Adults Age 18-60 Years Completed NCT02564471 Phase 4 Chloroquine;Atovaquone and Proguanil;Doxycycline
6 A Phase IV, Multi-center, Randomized, Open-label Study of PCECV (Rabipur®) Comparing the Immunogenicity and Safety of Two Different Simulated Post Exposure Schedules (Zagreb 2-1-1 Versus Essen Regimen 1-1-1-1-1) in Healthy Indian Subjects Completed NCT01365494 Phase 4
7 An Immunogenicity and Safety Study of Modified TRC-ID Regimen With A New Chromatographically Purified Vero Cell Rabies Vaccine(SPEEDA/TRCS SPEEDA) and Rabies Immunoglobulin Completed NCT01137045 Phase 4
8 Phase 4 Study of Speeda® Rabies Vaccine for Human Use Completed NCT01821911 Phase 4
9 Immunogenicity of a Two vs Three Dose, Intradermal (ID) vs Intramuscular (IM) Administration of a Licensed Rabies Vaccine for Pre-Exposure Vaccination Completed NCT02374814 Phase 4 Rabies vaccine;Placebo
10 A Phase IV, Open Label, Single-center Extension Study, to Evaluate the Long-term Persistence of Immune Responses After Post-exposure Prophylaxis With Purified Chicken-embryo Cell Rabies Vaccine in Chinese Children Completed NCT02991872 Phase 4
11 Safety of Rabivax-S in Individuals Receiving Pre-exposure Prophylaxis (PrEP) Completed NCT03741270 Phase 4
12 A Prospective Randomized Open Label Trial to Study the Systems Biology of Inactivated Rabies Vaccine in Healthy Adults With or Without Use of Broad Spectrum Antibiotics Recruiting NCT03557008 Phase 4 Metronidazole;Vancomycin;Neomycin Sulfate
13 Evaluation of Immune Response to Vaccines in Primary Immune Disorders Recruiting NCT00023504 Phase 4
14 Non-specific Effects of Rabies Vaccine on the Incidence of Common Infectious Disease Episodes: a Randomized Controlled Trial Enrolling by invitation NCT03656198 Phase 4 Sterile Water Injection
15 A Phase IV, Randomized, Open-label Study to Evaluate One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens (Zagreb 2-1-1 and Essen 1-1-1-1-1) in Chinese Children Withdrawn NCT03192371 Phase 4
16 A Prospective, Randomized, Double-Blind, Non Inferiority, Phase II/III Study of the Safety and Effectiveness of Simulated Post-Exposure Prophylaxis With Kamada Human Rabies Immune Globulin (KamRAB) With Co-administration of Active Rabies Vaccine in Healthy Subjects Unknown status NCT02040090 Phase 2, Phase 3 Active rabies vaccine (US-FDA approved)
17 Evaluate the Immunogenicity and Safety of Rabies Vaccine Given in a Post-exposure Prophylaxis Regimen to Healthy Children and Adults Aged 10-60 Years. Completed NCT00345319 Phase 3
18 Safety and Immunogenicity of Freeze-dried Rabies Vaccine(MRC-5 Cell) in Chinese Humans From 10-60 Years Old Completed NCT02288286 Phase 3
19 A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Different Preexposure Prophylaxis Schedules to Healthy Adult Subjects. Completed NCT01662440 Phase 3
20 Phase 3, Randomized, Stratified, Open Label, Multicenter, Controlled Clinical Study to Evaluate Safety and Immunogenicity of a Rabies Vaccine Administered, With and Without Human Rabies Immunoglobulin, Using the New "4-sites, 1-week" Intradermal Regimen for Postexposure Prophylaxis Compared to the Currently Recommended "2-sites, TRC" Intradermal Regimen in Children and Adults Subjects. Completed NCT02177032 Phase 3
21 Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine in Post-exposure Use in Healthy Subjects in China Completed NCT01339312 Phase 3
22 A Phase III, Single Center, Randomized, Open-label Study, Comparing PCECV Administered in the Abbreviated Zagreb Regimen (2-1-1) to the Conventional Essen Regimen (1-1-1-1-1) in Healthy Volunteers in China Completed NCT00825305 Phase 3
23 Immunogenicity and Safety of A Lyophilized Purified Human Diploid Cell Rabies Vaccine in Chinese Healthy People Aged 10-60 Years.: A Randomized, Blinded, Phase III Clinical Trial. Completed NCT03971370 Phase 3
24 A Single-centre, Randomized, Double-blind, Parallel Control, Phase 3 Study to Evaluate the Safety and Immunogenicity of a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects Aged 10-60 Years Completed NCT02491541 Phase 3
25 Compare Immunogenicity, Safety and Long-term Booster Response After Primary Vaccination With 2 Intradermal Doses Versus 3 Intradermal Doses of PCEC Rabies Vaccine (Rabipur) in Healthy School Children in Thailand (5-8 Years of Age) Completed NCT01107275 Phase 3
26 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults Completed NCT01466387 Phase 3
27 A Phase IIIb, Randomized, Open-label Study Comparing Two Different Rabies Vaccine Post-exposure Schedules (Zagreb 2-1-1 and Rabipur® Essen 1-1-1-1-1) in Chinese Children and Older Adults Completed NCT01680016 Phase 3
28 Simplifying the Rabies Pre-exposure Vaccination Completed NCT01388985 Phase 3
29 Safety and Immunogenicity Study of GSK Biologicals' Plasmodium Falciparum Malaria Vaccine 257049 Administered to HIV Infected Infants and Children Completed NCT01148459 Phase 3
30 Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Intradermal or Intramuscular Post-Exposure Prophylaxis Regimen at One Year Completed NCT03700242 Phase 3
31 A Prospective, Randomized, Double-Blind Parallel-group, Non-inferiority Phase II/III Study of the Safety and Effectiveness of BPL HRIG With Co Administration of Active Rabies Vaccine in Healthy Subjects Completed NCT03264157 Phase 2, Phase 3 HRIG;HyperRAB
32 Verorab® Immunogenicity and Safety After a One-week, 4-site, Intradermal (ID) Post-exposure Prophylaxis Regimen (4-4-4-0-0) Followed by a One-visit, 4-site, ID Booster at Five Years Completed NCT01622062 Phase 3
33 Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 6 μg HA/Strain/0.5 ml) for Children and Adolescents Completed NCT02387294 Phase 3
34 Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies Recruiting NCT02912845 Phase 3 KamRAB - HRIG
35 Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19 Recruiting NCT04342182 Phase 2, Phase 3
36 Efficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe Infection Recruiting NCT04385043 Phase 2, Phase 3 standard therapy
37 Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free in Comparison With Verorab® and Imovax® Rabies, in a Pre-exposure Regimen in Both Pediatric and Adult Populations and a Single Booster Dose of Purified Vero Rabies Vaccine - Serum Free Administered at 1 Year Post Primary Series in a Subset of Adults in Thailand Active, not recruiting NCT04127786 Phase 3
38 A Phase 3, Open-label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults Who Received Different Primary Vaccination Regimens of Pre-exposure Prophylaxis With Purified Chick-Embryo Cell Rabies Vaccine Administered Concomitantly or Separately From a Japanese Encephalitis Vaccine. Active, not recruiting NCT02545517 Phase 3
39 A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined Active, not recruiting NCT03143218 Phase 3 SMC with SP+AQ;SMC placebo
40 Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free in Comparison With Verorab® and Imovax® Rabies, in a Simulated Rabies Post-exposure Regimen in Healthy Adults in France Suspended NCT03965962 Phase 3
41 One-visit Multi-site Pre-exposure Intradermal Rabies Vaccination: Dose Finding in Healthy Adults. Unknown status NCT02276625 Phase 2
42 Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects. Completed NCT02559921 Phase 2
43 A Single-blind, Randomized, Monocentric Phase II Trial to Explore the Safety and Rabies-neutralizing Activity of Combined Administration of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin Plus Rabies Vaccine in Simulated Rabies Post-exposure Prophylaxis in Children and Adolescents Completed NCT00708084 Phase 2
44 Immunogenicity and Safety of a Purified Vero Rabies Vaccine Serum Free When Administered According to a Simulated Rabies Post Exposure Regimen in Healthy Adults Completed NCT03145766 Phase 2
45 A Randomized, Single-blind, Controlled, Monocentric Phase II Trial to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects Completed NCT00656097 Phase 2
46 Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Rabies Human Diploid Cell Vaccine (Imovax® Rabies) Administered in a Simulated Rabies Post-exposure Regimen in Healthy Adults Completed NCT01877395 Phase 2
47 Phase II Study to Determine the Efficacy and Safety of PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen Completed NCT02956421 Phase 2
48 A Three-Year Clinical Study on Immunogenicity, Safety and Booster Response of Purified Chick Embryo Cell Rabies Vaccine (Pcecv) Administered Intramuscularly or Intradermally to 12- to 18-Month-Old Thai Children Concomitantly With Japanese Encephalitis Vaccine Completed NCT00703521 Phase 2
49 Immunogenicity of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine in Pre-exposure Use in Healthy Adults Completed NCT00948272 Phase 2
50 A Randomized, Single-blind, Active-controlled, Mono-center Phase II Study to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Purified Vero Cell Rabies Vaccine vs. Human Rabies Immune Globulin or Placebo in Combination With Purified Vero Cell Rabies Vaccine vs. CL184 or Placebo in Combination With Human Diploid Cell Rabies Vaccine in Healthy Adult Subjects Completed NCT01228383 Phase 2

Search NIH Clinical Center for Rabies

Cochrane evidence based reviews: rabies

Genetic Tests for Rabies

Anatomical Context for Rabies

MalaCards organs/tissues related to Rabies:

40
Brain, Testes, Cortex, Kidney, T Cells, Spinal Cord, B Cells

Publications for Rabies

Articles related to Rabies:

(show top 50) (show all 13682)
# Title Authors PMID Year
1
Rabies in Uganda: rabies knowledge, attitude and practice and molecular characterization of circulating virus strains. 42 61
32143593 2020
2
Evaluation of post-exposure prophylaxis practices to improve the cost-effectiveness of rabies control in human cases potentially exposed to rabies in southern Bhutan. 61 42
32143641 2020
3
Economic and feasibility comparison of the dRIT and DFA for decentralized rabies diagnosis in resource-limited settings: The use of Nigerian dog meat markets as a case study. 42 61
32109246 2020
4
Modulation of HLA-G and HLA-E expression in human neuronal cells after rabies virus or herpes virus simplex type 1 infections. 61 54
17400066 2007
5
Immunohistochemical evaluation of mx protein expression in canine encephalitides. 61 54
17099155 2006
6
Expression of the interferon-alpha/beta-inducible bovine Mx1 dynamin interferes with replication of rabies virus. 61 54
16202617 2006
7
Modulation of HLA-G expression in human neural cells after neurotropic viral infections. 61 54
16306594 2005
8
High level of Bcl-2 counteracts apoptosis mediated by a live rabies virus vaccine strain and induces long-term infection. 61 54
14554083 2003
9
Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. 61 54
12660934 2003
10
B-cell responses to myelin basic protein and its epitopes in autoimmune encephalomyelitis induced by Semple rabies vaccine. 54 61
10430042 1999
11
Antibodies to human myelin proteins and gangliosides in patients with acute neuroparalytic accidents induced by brain-derived rabies vaccine. 54 61
9846820 1998
12
Molecular mimicry between the rabies virus glycoprotein and human immunodeficiency virus-1 GP120: cross-reacting antibodies induced by rabies vaccination. 61 54
9345046 1997
13
Clonal analysis of a human antibody response. II. Sequences of the VH genes of human IgM, IgG, and IgA to rabies virus reveal preferential utilization of VHIII segments and somatic hypermutation. 61 54
8432980 1993
14
Immunization of monkeys with rabies ribonucleoprotein (RNP) confers protective immunity against rabies. 61 54
2058261 1991
15
Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. 54 61
2153188 1990
16
Unexpected rabies variant identified in kinkajou (Potos flavus), Mato Grosso, Brazil. 61
32403984 2020
17
Neuronal mitochondria-targeted therapy for Alzheimer's disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems. 61
32228100 2020
18
Interdisciplinary aspects of possible negative effects of dogs on humans in Bosnia and Herzegovina. 61
32567293 2020
19
Hypothesized behavioral host manipulation by SARS-CoV2/COVID-19 infection. 61
32388138 2020
20
Bat and Lyssavirus Exposure among Humans in Area that Celebrates Bat Festival, Nigeria, 2010 and 2013. 61
32568051 2020
21
Glutamatergic and gabaergic neuronal populations in the dorsal Periacqueductual Gray have different functional roles in aversive conditioning. 61
32454151 2020
22
Molecular study of rabies virus in slaughtered dogs in Billiri and Kaltungo local government areas of Gombe state, Nigeria. 61
32243880 2020
23
Characterization of the Th17 profile immune response in cases of human rabies transmitted by dogs and its interference in the disease pathogenesis. 61
32416557 2020
24
Multiple areas of the cerebral cortex influence the stomach. 61
32434910 2020
25
New Cerebello-Cortical Pathway Involved in Higher-Order Oculomotor Control. 61
32076936 2020
26
Estimation of dog population and dog bite risk factors in departments of San Pedro and Bouake in Côte d'Ivoire. 61
32194069 2020
27
A novel electrophoretic immunoblot as antigen desorption and quantification method for alum-adjuvanted veterinary rabies vaccines. 61
32402753 2020
28
Evaluation of polyclonal anti-RNP IgG antibody for rabies diagnosis by indirect rapid immunohistochemistry test. 61
32092291 2020
29
Short communication on the use of a free rabies hotline service in Chad. 61
32184101 2020
30
A Phase 3, Randomised, Open-Label, Non-inferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG). 61
32556113 2020
31
Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor. 61
32321812 2020
32
Comparison of five different laboratory techniques for the rabies diagnosis in clinically suspected cattle in Brazil. 61
32554044 2020
33
Where and when to vaccinate? Interdisciplinary design and evaluation of the 2018 Tanzanian anti-rabies campaign. 61
32205283 2020
34
Preparation and qualification of internal rabies reference standards for use in the rabies rapid fluorescent focus inhibition test. 61
32555434 2020
35
Variation in host home range size decreases rabies vaccination effectiveness by increasing the spatial spread of rabies virus. 61
31957005 2020
36
COVID-19 and Laparoscopic Surgery: Scoping Review of Current Literature and Local Expertise. 61
32406853 2020
37
The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial. 61
32503657 2020
38
Immunogenicity and safety of two-visit, intradermal pre-exposure rabies prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis vaccine in children living in rabies and Japanese encephalitis endemic country. 61
32522414 2020
39
Oligomerization of the Vesicular Stomatitis Virus Phosphoprotein Is Dispensable for mRNA Synthesis but Facilitates RNA Replication. 61
32321813 2020
40
Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults. 61
32386747 2020
41
Triterpenoid and saponin rich Phytolacca dodecandra L'Herit(Endod): A review on its phytochemistry and pharmacological properties. 61
32552643 2020
42
Whole-Brain Monosynaptic Inputs to Hypoglossal Motor Neurons in Mice. 61
32096114 2020
43
From Conifers to Cognition: Microbes, Brain, and Behavior. 61
32515128 2020
44
GLUT-1: An Effective Target To Deliver Brain-Derived Neurotrophic Factor Gene Across the Blood Brain Barrier. 61
32352752 2020
45
Epitope-based sieve analysis of Plasmodium falciparum sequences from a FMP2.1/AS02A vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants. 61
32571720 2020
46
Animal rabies situation in Sultanate of Oman (2017-2019). 61
32564218 2020
47
Fight against rabies in Nepal: Immediate need for government intervention. 61
32140536 2020
48
A novel rabies vaccine based on infectious propagating particles derived from hybrid VEEV-Rabies replicon. 61
32512518 2020
49
[Rabies: Prevention strategies for travellers]. 61
32514954 2020
50
Detection of rabies virus antigen by the indirect rapid immunohistochemistry test in equines and comparisons with other diagnostic techniques. 61
32537888 2020

Variations for Rabies

Expression for Rabies

Search GEO for disease gene expression data for Rabies.

Pathways for Rabies

Pathways related to Rabies according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 TLR3 STAT2 STAT1 PTPN4 PML NCAM1
2
Show member pathways
13.26 STAT2 STAT1 PML NCAM1 MX1 IRF7
3
Show member pathways
13 TLR3 STAT2 STAT1 MX1 IRF7 IRF3
4
Show member pathways
12.91 TLR3 STAT2 STAT1 NGFR MX1 IRF3
5
Show member pathways
12.88 TLR3 STAT2 STAT1 IRF7 IRF3 IFNA1
6 12.75 TLR3 STAT2 STAT1 PML IRF7 IRF3
7
Show member pathways
12.7 TLR3 STAT2 STAT1 PML MX1 IRF7
8
Show member pathways
12.6 TLR3 STAT1 IRF7 IRF3 IFNA1
9
Show member pathways
12.49 TLR3 IRF7 IRF3 IFNA1 DDX58 CXCL10
10
Show member pathways
12.47 IRF7 IRF3 IFNA1 DHX58 DDX58 CXCL10
11 12.18 STAT2 STAT1 IRF7 IRF3 IFNA1
12
Show member pathways
12.18 STAT2 STAT1 PML NGFR MX1 IRF7
13
Show member pathways
12.15 STAT2 STAT1 PML NCAM1 MX1 IRF7
14
Show member pathways
12.09 TLR3 STAT2 STAT1 IFNA1
15 11.88 TLR3 STAT2 STAT1 NCAM1 IRF7 IRF3
16
Show member pathways
11.79 TLR3 STAT2 STAT1
17 11.71 STAT2 STAT1 IFNA1
18 11.29 STAT2 STAT1 CXCL10
19
Show member pathways
10.99 STAT2 STAT1 MX1 IRF7 IRF3 DDX58

GO Terms for Rabies

Cellular components related to Rabies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 TLR3 STAT2 STAT1 PTPN4 PML OCA2

Biological processes related to Rabies according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 TLR3 STAT2 STAT1 IRF7 IRF3 DDX58
2 immune system process GO:0002376 10.08 TLR3 PML MX1 IRF7 IRF3 HLA-G
3 innate immune response GO:0045087 10.05 TLR3 PML MX1 IRF7 IRF3 DHX58
4 viral process GO:0016032 9.97 STAT2 STAT1 PML NCAM1 IRF7 IRF3
5 cytokine-mediated signaling pathway GO:0019221 9.92 STAT2 STAT1 IFNA1 CXCL10
6 defense response GO:0006952 9.91 TLR3 STAT2 STAT1 MX1 IFNA1 CXCL10
7 negative regulation of angiogenesis GO:0016525 9.88 STAT1 PML HLA-G CXCL10
8 response to virus GO:0009615 9.85 TLR3 MX1 IRF7 DHX58 DDX58 CXCL10
9 positive regulation of type I interferon production GO:0032481 9.8 TLR3 IRF7 IRF3 DHX58
10 response to exogenous dsRNA GO:0043330 9.76 TLR3 IRF3 IFNA1 DDX58
11 negative regulation of type I interferon production GO:0032480 9.73 IRF3 DHX58 DDX58
12 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.72 TLR3 IRF7 IRF3
13 positive regulation of interleukin-12 production GO:0032735 9.71 TLR3 HLA-G CD40LG
14 positive regulation of interferon-alpha production GO:0032727 9.71 STAT1 IRF7 IRF3 DDX58
15 cellular response to exogenous dsRNA GO:0071360 9.7 TLR3 IRF3 DDX58
16 positive regulation of interferon-beta production GO:0032728 9.65 TLR3 IRF7 IRF3 DHX58 DDX58
17 interferon-gamma-mediated signaling pathway GO:0060333 9.63 STAT1 PML NCAM1 IRF7 IRF3 HLA-G
18 regulation of type I interferon production GO:0032479 9.61 IRF7 IRF3
19 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.61 IRF7 IRF3
20 detection of virus GO:0009597 9.59 TLR3 DDX58
21 type I interferon biosynthetic process GO:0045351 9.58 IRF7 IRF3
22 MDA-5 signaling pathway GO:0039530 9.57 IRF7 IRF3
23 type I interferon signaling pathway GO:0060337 9.5 STAT2 STAT1 MX1 IRF7 IRF3 IFNA1
24 defense response to virus GO:0051607 9.36 TLR3 STAT2 STAT1 PML MX1 IRF7

Molecular functions related to Rabies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 TLR3 STAT2 STAT1 PTPN4 PML OCA2
2 double-stranded RNA binding GO:0003725 9.33 TLR3 DHX58 DDX58
3 identical protein binding GO:0042802 9.23 TLR3 STAT2 STAT1 MX1 IRF3 HLA-G

Sources for Rabies

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....